Literature DB >> 33839688

Exercise Training Improves Tumor Control by Increasing CD8+ T-cell Infiltration via CXCR3 Signaling and Sensitizes Breast Cancer to Immune Checkpoint Blockade.

Igor L Gomes-Santos1, Zohreh Amoozgar1, Ashwin S Kumar1,2, William W Ho1, Kangsan Roh1, Nilesh P Talele1, Hannah Curtis1, Kosuke Kawaguchi1, Rakesh K Jain3, Dai Fukumura3.   

Abstract

The mechanisms behind the antitumor effects of exercise training (ExTr) are not fully understood. Using mouse models of established breast cancer, we examined here the causal role of CD8+ T cells in the benefit acquired from ExTr in tumor control, as well as the ability of ExTr to improve immunotherapy responses. We implanted E0771, EMT6, MMTV-PyMT, and MCa-M3C breast cancer cells orthotopically in wild-type or Cxcr3-/- female mice and initiated intensity-controlled ExTr sessions when tumors reached approximately 100 mm3 We characterized the tumor microenvironment (TME) using flow cytometry, transcriptome analysis, proteome array, ELISA, and immunohistochemistry. We used antibodies against CD8+ T cells for cell depletion. Treatment with immune checkpoint blockade (ICB) consisted of anti-PD-1 alone or in combination with anti-CTLA-4. ExTr delayed tumor growth and induced vessel normalization, demonstrated by increased pericyte coverage and perfusion and by decreased hypoxia. ExTr boosted CD8+ T-cell infiltration, with enhanced effector function. CD8+ T-cell depletion prevented the antitumor effect of ExTr. The recruitment of CD8+ T cells and the antitumor effects of ExTr were abrogated in Cxcr3-/- mice, supporting the causal role of the CXCL9/CXCL11-CXCR3 pathway. ExTr also sensitized ICB-refractory breast cancers to treatment. Our results indicate that ExTr can normalize the tumor vasculature, reprogram the immune TME, and enhance the antitumor activity mediated by CD8+ T cells via CXCR3, boosting ICB responses. Our findings and mechanistic insights provide a rationale for the clinical translation of ExTr to improve immunotherapy of breast cancer. ©2021 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33839688      PMCID: PMC8295193          DOI: 10.1158/2326-6066.CIR-20-0499

Source DB:  PubMed          Journal:  Cancer Immunol Res        ISSN: 2326-6066            Impact factor:   11.151


  71 in total

1.  Modulation of microenvironment acidity reverses anergy in human and murine tumor-infiltrating T lymphocytes.

Authors:  Arianna Calcinotto; Paola Filipazzi; Matteo Grioni; Manuela Iero; Angelo De Milito; Alessia Ricupito; Agata Cova; Rossella Canese; Elena Jachetti; Monica Rossetti; Veronica Huber; Giorgio Parmiani; Luca Generoso; Mario Santinami; Martina Borghi; Stefano Fais; Matteo Bellone; Licia Rivoltini
Journal:  Cancer Res       Date:  2012-05-16       Impact factor: 12.701

Review 2.  Effects and moderators of exercise on quality of life and physical function in patients with cancer: An individual patient data meta-analysis of 34 RCTs.

Authors:  Laurien M Buffart; Joeri Kalter; Maike G Sweegers; Kerry S Courneya; Robert U Newton; Neil K Aaronson; Paul B Jacobsen; Anne M May; Daniel A Galvão; Mai J Chinapaw; Karen Steindorf; Melinda L Irwin; Martijn M Stuiver; Sandi Hayes; Kathleen A Griffith; Alejandro Lucia; Ilse Mesters; Ellen van Weert; Hans Knoop; Martine M Goedendorp; Nanette Mutrie; Amanda J Daley; Alex McConnachie; Martin Bohus; Lene Thorsen; Karl-Heinz Schulz; Camille E Short; Erica L James; Ron C Plotnikoff; Gill Arbane; Martina E Schmidt; Karin Potthoff; Marc van Beurden; Hester S Oldenburg; Gabe S Sonke; Wim H van Harten; Rachel Garrod; Kathryn H Schmitz; Kerri M Winters-Stone; Miranda J Velthuis; Dennis R Taaffe; Willem van Mechelen; Marie-José Kersten; Frans Nollet; Jennifer Wenzel; Joachim Wiskemann; Irma M Verdonck-de Leeuw; Johannes Brug
Journal:  Cancer Treat Rev       Date:  2016-12-05       Impact factor: 12.111

3.  BL-8040, a CXCR4 antagonist, in combination with pembrolizumab and chemotherapy for pancreatic cancer: the COMBAT trial.

Authors:  Bruno Bockorny; Valerya Semenisty; Teresa Macarulla; Erkut Borazanci; Brian M Wolpin; Salomon M Stemmer; Talia Golan; Ravit Geva; Mitesh J Borad; Katrina S Pedersen; Joon Oh Park; Robert A Ramirez; David G Abad; Jaime Feliu; Andres Muñoz; Mariano Ponz-Sarvise; Amnon Peled; Tzipora M Lustig; Osnat Bohana-Kashtan; Stephen M Shaw; Ella Sorani; Marya Chaney; Shaul Kadosh; Abi Vainstein Haras; Daniel D Von Hoff; Manuel Hidalgo
Journal:  Nat Med       Date:  2020-05-25       Impact factor: 53.440

4.  β2-Adrenergic receptor signaling mediates the preferential mobilization of differentiated subsets of CD8+ T-cells, NK-cells and non-classical monocytes in response to acute exercise in humans.

Authors:  Rachel M Graff; Hawley E Kunz; Nadia H Agha; Forrest L Baker; Mitzi Laughlin; Austin B Bigley; Melissa M Markofski; Emily C LaVoy; Emmanuel Katsanis; Richard A Bond; Catherine M Bollard; Richard J Simpson
Journal:  Brain Behav Immun       Date:  2018-08-30       Impact factor: 7.217

5.  Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression.

Authors:  Chih-Hao Chang; Jing Qiu; David O'Sullivan; Michael D Buck; Takuro Noguchi; Jonathan D Curtis; Qiongyu Chen; Mariel Gindin; Matthew M Gubin; Gerritje J W van der Windt; Elena Tonc; Robert D Schreiber; Edward J Pearce; Erika L Pearce
Journal:  Cell       Date:  2015-08-27       Impact factor: 41.582

6.  Blood flow responses to mild-intensity exercise in ectopic vs. orthotopic prostate tumors; dependence upon host tissue hemodynamics and vascular reactivity.

Authors:  Emmanuel Garcia; Veronika G C Becker; Danielle J McCullough; John N Stabley; Elizabeth M Gittemeier; Alexander B Opoku-Acheampong; Dietmar W Sieman; Bradley J Behnke
Journal:  J Appl Physiol (1985)       Date:  2016-04-28

7.  Role of Cytotoxic Tumor-Infiltrating Lymphocytes in Predicting Outcomes in Metastatic HER2-Positive Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial.

Authors:  Shuzhen Liu; Bingshu Chen; Samantha Burugu; Samuel Leung; Dongxia Gao; Shakeel Virk; Zuzana Kos; Wendy R Parulekar; Lois Shepherd; Karen A Gelmon; Torsten O Nielsen
Journal:  JAMA Oncol       Date:  2017-11-09       Impact factor: 31.777

8.  Migratory properties of naive, effector, and memory CD8(+) T cells.

Authors:  W Weninger; M A Crowley; N Manjunath; U H von Andrian
Journal:  J Exp Med       Date:  2001-10-01       Impact factor: 14.307

9.  Tumor vessel normalization after aerobic exercise enhances chemotherapeutic efficacy.

Authors:  Keri L Schadler; Nicholas J Thomas; Peter A Galie; Dong Ha Bhang; Kerry C Roby; Prince Addai; Jacob E Till; Kathleen Sturgeon; Alexander Zaslavsky; Christopher S Chen; Sandra Ryeom
Journal:  Oncotarget       Date:  2016-10-04

10.  Cytotoxic T-cells mediate exercise-induced reductions in tumor growth.

Authors:  Helene Rundqvist; Pedro Veliça; Laura Barbieri; Paulo A Gameiro; David Bargiela; Milos Gojkovic; Sara Mijwel; Stefan Markus Reitzner; David Wulliman; Emil Ahlstedt; Jernej Ule; Arne Östman; Randall S Johnson
Journal:  Elife       Date:  2020-10-23       Impact factor: 8.140

View more
  11 in total

Review 1.  Reframing How Physical Activity Reduces The Incidence of Clinically-Diagnosed Cancers: Appraising Exercise-Induced Immuno-Modulation As An Integral Mechanism.

Authors:  Annabelle Emery; Sally Moore; James E Turner; John P Campbell
Journal:  Front Oncol       Date:  2022-03-14       Impact factor: 6.244

2.  Identification of immune-related biomarkers for predicting neoadjuvant chemotherapy sensitivity in HER2 negative breast cancer via bioinformatics analysis.

Authors:  Dalang Fang; Yanting Li; Yanghong Li; Yongcheng Chen; Qianfang Huang; Zhizhai Luo; Jinghua Chen; Yingjin Li; Zaizhi Wu; Yuanlu Huang; Yanfei Ma
Journal:  Gland Surg       Date:  2022-06

Review 3.  Tumor immune microenvironment and systemic response in breast cancer.

Authors:  Kosuke Kawaguchi; Yurina Maeshima; Masakazu Toi
Journal:  Med Oncol       Date:  2022-09-29       Impact factor: 3.738

4.  Exercise-induced engagement of the IL-15/IL-15Rα axis promotes anti-tumor immunity in pancreatic cancer.

Authors:  Emma Kurz; Carolina Alcantara Hirsch; Tanner Dalton; Sorin Alberto Shadaloey; Alireza Khodadadi-Jamayran; George Miller; Sumedha Pareek; Hajar Rajaei; Chirayu Mohindroo; Seyda Baydogan; An Ngo-Huang; Nathan Parker; Matthew H G Katz; Maria Petzel; Emily Vucic; Florencia McAllister; Keri Schadler; Rafael Winograd; Dafna Bar-Sagi
Journal:  Cancer Cell       Date:  2022-06-02       Impact factor: 38.585

5.  Dual near-infrared II laser modulates the cellular redox state of T cells and augments the efficacy of cancer immunotherapy.

Authors:  Wataru Katagiri; Shinya Yokomizo; Takanobu Ishizuka; Keiko Yamashita; Timo Kopp; Malte Roessing; Akiko Sato; Taizo Iwasaki; Hideki Sato; Takeshi Fukuda; Hailey Monaco; Sophia Manganiello; Shinsuke Nomura; Mei Rosa Ng; Susanne Feil; Emiyu Ogawa; Dai Fukumura; Dmitriy N Atochin; Hak Soo Choi; Satoshi Kashiwagi
Journal:  FASEB J       Date:  2022-10       Impact factor: 5.834

Review 6.  Role of chemokine systems in cancer and inflammatory diseases.

Authors:  Hongyi Li; Min Wu; Xia Zhao
Journal:  MedComm (2020)       Date:  2022-06-08

7.  Activation of the chemokine receptor 3 pathway leads to a better response to immune checkpoint inhibitors in patients with metastatic urothelial carcinoma.

Authors:  Wenqin Feng; Anqi Lin; Le Sun; Ting Wei; Haoxuan Ying; Jian Zhang; Peng Luo; Weiliang Zhu
Journal:  Cancer Cell Int       Date:  2022-05-13       Impact factor: 6.429

8.  The Predictive Value of PAK7 Mutation for Immune Checkpoint Inhibitors Therapy in Non-Small Cell Cancer.

Authors:  Hao Zeng; Fan Tong; Yawen Bin; Ling Peng; Xuan Gao; Xuefeng Xia; Xin Yi; Xiaorong Dong
Journal:  Front Immunol       Date:  2022-02-03       Impact factor: 8.786

Review 9.  Pharmacotherapy for Advanced Non-Small Cell Lung Cancer with Performance Status 2 without Druggable Gene Alterations: Could Immune Checkpoint Inhibitors Be a Game Changer?

Authors:  Satoshi Ikeda; Tateaki Naito; Satoru Miura; Kentaro Ito; Naoki Furuya; Toshihiro Misumi; Takashi Ogura; Terufumi Kato
Journal:  Cancers (Basel)       Date:  2022-10-05       Impact factor: 6.575

Review 10.  The Effects of Physical Activity on Cancer Patients Undergoing Treatment with Immune Checkpoint Inhibitors: A Scoping Review.

Authors:  Amy L Shaver; Swapnil Sharma; Nikita Nikita; Daniel S Lefler; Atrayee Basu-Mallick; Jennifer M Johnson; Meghan Butryn; Grace Lu-Yao
Journal:  Cancers (Basel)       Date:  2021-12-18       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.